Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A squamous cell carcinoma arising from the cervical epithelium. It usually evolves from a precancerous cervical lesion. Increased numbers of sexual partners and human papillomavirus (HPV) infection are risk factors for cervical squamous cell carcinoma. The following histologic patterns have been described: conventional squamous cell carcinoma, papillary squamous cell carcinoma, transitional cell carcinoma, lymphoepithelioma-like carcinoma, verrucous carcinoma, condylomatous carcinoma and spindle cell carcinoma. Survival is most closely related to the stage of disease at the time of diagnosis.
Biomarker and diagnostic research for cervical squamous cell carcinoma has been reported in the published literature.
26 clinical trials registered, 9 recruiting. Interventions under study include drug therapy, procedural interventions, other interventions, and biologic therapy. Pipeline includes 3 PHASE3, 5 PHASE2, 10 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT05910827](https://clinicaltrials.gov/study/NCT05910827) |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 7:49 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers |
PHASE1 |
Hummingbird Bioscience |
RECRUITING |
[NCT06747585](https://clinicaltrials.gov/study/NCT06747585) | A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors | PHASE1 | Alentis Therapeutics AG | RECRUITING |
[NCT06543576](https://clinicaltrials.gov/study/NCT06543576) | External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer | PHASE1 | Jonsson Comprehensive Cancer Center | RECRUITING |
[NCT06256224](https://clinicaltrials.gov/study/NCT06256224) | Toripalimab Combined With Definitive CCRT for LACC Patients | NA | Ruijin Hospital | RECRUITING |
[NCT04712851](https://clinicaltrials.gov/study/NCT04712851) | Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia | PHASE2 | Jonsson Comprehensive Cancer Center | RECRUITING |
257 publications have been identified in PubMed for cervical squamous cell carcinoma. Research spans Basic Science / Preclinical (37%), Diagnostic / Biomarker (28%), and Epidemiology / Natural History (11%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 96 | 37% |
Testing and diagnosis research | 72 | 28% |
Disease patterns and progression | 28 | 11% |
Patient case studies | 25 | 10% |
Research summaries | 16 | 6% |
Clinical study results | 12 | 5% |
New treatment approaches | 6 | 2% |
Other research | 2 | 1% |
Lu S (2026). [PMID: 42038463](https://pubmed.ncbi.nlm.nih.gov/42038463/). *PeerJ*. [Basic Science / Preclinical]
Chen C (2026). [PMID: 41877370](https://pubmed.ncbi.nlm.nih.gov/41877370/). *Sci Prog*. [Diagnostic / Biomarker]
Xu M (2026). [PMID: 42012232](https://pubmed.ncbi.nlm.nih.gov/42012232/). *Hum Vaccin Immunother*. [Review / Meta-Analysis]
Bendari A (2026). [PMID: 41451979](https://pubmed.ncbi.nlm.nih.gov/41451979/). *Int J Surg Pathol*. [Case Report / Case Series]
Sapienza LG (2026). [PMID: 40972906](https://pubmed.ncbi.nlm.nih.gov/40972906/). *Int J Radiat Oncol Biol Phys*. [Review / Meta-Analysis]
Lei T (2026). [PMID: 41964419](https://pubmed.ncbi.nlm.nih.gov/41964419/). *J Med Virol*. [Clinical Trial Publication]
Zhao C (2026). [PMID: 41731703](https://pubmed.ncbi.nlm.nih.gov/41731703/). *Int J Surg Pathol*. [Review / Meta-Analysis]
Zhao Y (2026). [PMID: 41795093](https://pubmed.ncbi.nlm.nih.gov/41795093/). *BMC Cancer*. [Diagnostic / Biomarker]
Zhou Y (2026). [PMID: 42265073](https://pubmed.ncbi.nlm.nih.gov/42265073/). *Cell Death Dis*. [Basic Science / Preclinical]
Nandi R (2026). [PMID: 41523343](https://pubmed.ncbi.nlm.nih.gov/41523343/). *Indian J Radiol Imaging*. [Diagnostic / Biomarker]
AI-curated news mentioning cervical squamous cell carcinoma
Updated Aug 26, 2026
A case report highlights an unusual cecal metastasis originating from primary cervical squamous cell carcinoma. This finding may provide insights into the metastatic behavior of cervical cancer.
A new study explores the use of interventional radiotherapy (brachytherapy) for organ-sparing treatment of invasive squamous cell cancer of the nasal vestibule. This approach may offer a promising alternative for patients, preserving nasal function while targeting cancerous cells.